🚨 NATALEE: Kisqali® + ET reduced death risk by ~20% in high-risk HR+/HER2− early breast cancer (OS HR 0.809). 6-year iDFS benefit: 5.3%.

ONCOassist® | The go-to oncology app· @ONCOassist · X·2026-10-24 23:00· 16 hours agoScore70

Body · original

🔗 https://campaign.oncoassist.com/XesmoCon2

📍 Attending ESMO Congress 2026? Visit ONCOassist at Booth 1091.

#BreastCancer #ESMO26

30 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

Source: ONCOassist® | The go-to oncology app · x.com